Soleus Capital Management, L.P. Revance Therapeutics, Inc. Transaction History

Soleus Capital Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$26.8 - $31.84 $834,444 - $991,370	-31,136 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$23.41 - $28.34 $245,360 - $297,031	-10,481 Reduced 25.18%	31,136 $882,000
Q3 2020 Nov 13, 2020	BUY	$23.23 - $34.3 $305,428 - $450,976	13,148 Added 46.18%	41,617 $1.05 Million
Q2 2020 Aug 14, 2020	BUY	$12.6 - $26.55 $209,160 - $440,730	16,600 Added 139.86%	28,469 $695,000
Q1 2020 May 15, 2020	SELL	$12.46 - $27.81 $141,184 - $315,115	-11,331 Reduced 48.84%	11,869 $176,000
Q4 2019 Feb 14, 2020	BUY	$11.66 - $20.15 $270,512 - $467,479	23,200 New	23,200 $376,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Soleus Capital Management, L.P. with notifications on news.